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Damage to the lateral hypothalamus (LH) causes profound physical
inactivity inmammals. Several molecularly distinct types of LH neurons
have been identified, including orexin cells and glutamic acid decar-
boxylase 65 (GAD65) cells, but their interplay in orchestrating physical
activity is not fully understood. Here, using optogenetic circuit analysis
and cell type-specific deep-brain recordings in behaving mice, we
show that orexin cell activation rapidly recruits GAD65LH neurons. We
demonstrate that internally initiated GAD65LH cell bursts precede and
accompany spontaneous running bouts, that selective chemogenetic
silencing of natural GAD65LH cell activity depresses voluntary locomo-
tion, and that GAD65LH cell overactivation leads to hyperlocomotion.
These results thus identify a molecularly distinct, orexin-activated
LH submodule that governs physical activity in mice.
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The lateral hypothalamus (LH) is thought to provide an es-sential drive for diverse vital behaviors, including locomotion.
Peri-LH lesions in mammals disrupt context-appropriate physical
activity, and are associated with the human disorder encephalitis
lethargica, which has been noted to make humans “sit motion-
less. . .all day” (1–6). The LH is not a homogeneous entity, but
contains many molecularly distinct classes of neurons that are
thought to have different physiological roles (7). However, the
interrelations of distinct LH cell classes in computing and driving
context-appropriate physical activity are not fully understood.
For example, LH neurons expressing orexins/hypocretins (8, 9)
become activated in diverse stressful contexts, including acute au-
ditory stimulation, hypoglycemia, hypercapnia, and physical capture
(3, 9–13). OrexinLH cell activity may thus represent an important
input variable for computing context-appropriate locomotor outputs
(3, 14), and orexin peptides have been proposed to increase arousal
and locomotion by actions on extrahypothalamic projections to areas
such as the locus coeruleus (15, 16). However, hypoactivity pheno-
types caused by orexinLH cell deletion are milder than the hypo-
activity phenotypes caused by broader LH lesions (1–3, 5, 12, 13,
17–19), whereas melanin-concentrating hormone LH (MCHLH) cell
deletion causes hyperactivity, implying that MCHLH cells suppress
locomotion (20). These findings suggest that additional drivers
of physical activity may exist in the LH.
It was recently found that LH neurons expressing glutamic acid
decarboxylase 65 (GAD65) are distinct from orexin and MCH
neurons (21). We hypothesized that these cells may be a source of
natural LH signals underlying normal levels of physical activity.
Here, we investigate this hypothesis by using a combination of cell
type-specific manipulation and recording techniques. We find that
GAD65LH cells operate as a stress- and orexin-activated LH
module whose physiological activity is essential for normal loco-
motion, and whose hyperactivity causes hyperlocomotion.
Results
Orexin and Stress Rapidly Recruit GAD65LH Neurons. To examine
whether orexin cells communicate with GAD65LH cells, we tar-
geted the light-activated excitatory actuator channelrhodpsin-2
(ChR2) to orexin cells, enabling selective optical activation of
orexin-ChR2 cells (22). We then examined resulting optically in-
duced postsynaptic responses in GAD65LH neurons (Fig. 1A; group
data and/or statistics for findings illustrated as figures are described
in the figure legends). We found that GAD65LH cells received time-
locked excitatory glutamatergic inputs when orexinLH cells were
stimulated (Fig. 1A). To determine if orexin peptide signaling drives
the GAD65LH network, we also investigated the effect of applying
exogenous orexin peptide. We used confocal network imaging of a
Cre-dependent calcium indicator, GCaMP6s (23), expressed in LH
slices from GAD65-Ires-Cre mice (Fig. 1B). Orexin-A peptide ro-
bustly excited the GAD65LH network, and this excitation persisted
(but was slightly reduced) in the presence of a mix of synaptic
blockers (Fig. 1B). In parallel, electrophysiological recordings
showed that orexin excites individual GAD65LH cells by activating a
current with a reversal potential consistent with a nonselective
cationic conductance (Fig. 1C). Overall, >98% of GAD65LH cells
(64 of 65 cells) were activated by orexin peptide in vitro.
If orexin cells also activate GAD65LH cells in vivo, then stress
stimuli that elicit orexinLH cell activity should also activate
GAD65LH cells in vivo. Acute immobilization stress rapidly and
robustly activates orexinLH cells in awake mice (13). We therefore
used this paradigm, combined with deep-brain fiber photometry
recording of GAD65LH cell activity and pharmacological anta-
gonism of orexin receptors, to determine if stress and orexin
drive GAD65LH cell activity in vivo. We expressed Cre-dependent
GCaMP6s, or control protein EGFP, in the LH of GAD65-Ires-
Cre mice, and recorded fluorescence intensity using a fiberoptic
probe implanted in the LH (Fig. 2A). We observed bursts of ac-
tivity in GAD65LH-GCaMP6s cells, but not in GAD65LH-EGFP
cells, of freely moving mice (Fig. 2A). These bursts were similar
(≈5–30% ΔF/F) to the bursts recorded using photometry in
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other deep networks, and are thought to represent network
firing bursts (24–26). Using simultaneous electrical recordings
and GCaMP6s imaging from the same GAD65LH-GCaMP6s
cells in vitro, we confirmed that GCaMP6s linearly reports
spike firing rate (Fig. 2 B–D), with a mean slope (≈1% ΔF/F
per hertz; Fig. 2D) similar to the mean slope observed in other
LH neurons (12, 13). Upon acute immobilization, we observed
rapid activation of GAD65LH-GCaMP6s cells, but not control
GAD65LH-GFP cells (Fig. 2E; peak amplitude of stress-induced
GAD65LH-GCaMP6s activity transient was 12.3 ± 2.7%; P = 0.0174
by one-sample t test: t, df = 4.782, 3; n = 4 mice). The competitive
orexin receptor antagonist SB-334867 (Materials and Methods)
reversibly reduced this stress-induced activation of GAD65LH cells
(Fig. 2E).
Collectively, these data identify the orexin system as a physi-
ologically relevant upstream activator of GAD65LH neurons.
GAD65LH Cell Activity Drives (and Correlates with) Voluntary Locomotion.
We next tested whether the GAD65LH module could act as an
LH effector of physical activity. To probe causal links between
GAD65LH cell activity and locomotion, we explored locomotor
effects of selective silencing or activation of GAD65LH cell ac-
tivity in freely moving mice.
First, we targeted the neuroinhibitory clozapine-N-oxide (CNO)
receptor hM4Di (27) to the LH of GAD65-Ires-Cre transgenic
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Fig. 1. Evidence for orexinLH → GAD65LH excitatory circuit. (A) Optogenetic interrogation of orexinLH → GAD65LH signaling. (Left) Targeting strategy. (Center,
Left and Right) Localization of orexin-ChR2-mCherry and GAD65-GFP expression (representative example of five brains). (Right) Orexin cell photostimulation
(vertical blue line) evokes a CNQX/D-AP5–sensitive (i.e., glutamate receptor-mediated) inward current in a GAD65LH cell. Gray lines are individual trials, and
colored lines are trial averages [representative example of five cells; ≈80% cells (n = 5/6 cells) were connected]. (B) Effects of orexin peptide on GAD65LH network
activity. Scheme for targeting GCaMP6s (Left), example of GCaMP6s expression in GAD65LH cells (representative example of five brains) (Center Left), GCaMP6s
response of GAD65LH cells to 300 nM orexin-A with corresponding mean ± SEM plot (n = 44) (Center Right), and data summary without (C) and with (B) synaptic
blockers (n = 44 and n = 13 cells, respectively, mean ± SEM responses of cells during 2–20min after orexin-A infusion) (Right). P values (italics) are from sign tests of
whether the response within each group is different from zero, and P value (regular font) is from a two-tailed Mann–Whitney test comparing response amplitude
between groups. (C) Effects of orexin peptide on GAD65LH cell electrical activity. (Left) Membrane potential effect of 300 nM orexin-A on a GAD65LH cell
(representative example of six cells). syn., synaptic. (Center) Example of whole-cell current–voltage relation showing effect of orexin-A (representative example of
five cells). (Right) Net orexin-activated current (mean and SEM of n = 5 cells).
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mice (Fig. 3A). This procedure enabled GAD65LH cell inhibition
by CNO (Fig. 3B). Inhibition of GAD65LH-hM4Di cells in freely
behaving mice substantially reduced their voluntary locomotion
(by an average of ≈50%, as shown in Fig. 3 C and D; no such
effect was seen in control GAD65LH-ChR2 mice, in which the
CNO-induced change in locomotion was 4.6 ± 8.2%, n = 5, P =
0.6016 by one-sample t test: t, df = 0.0566, 4). Interestingly, orexin
receptor blockade with SB-334867 reduced voluntary locomotion
under control conditions, but not when GAD65LH-hM4Di cells
were inactivated with CNO (Fig. 3D and Discussion).
Next, we targeted the neuroexcitatory CNO receptor hM3Dq
(27) to the LH of GAD65-Ires-Cre transgenic mice (Fig. 3 E and
F). Stimulation of GAD65LH-hM3Dq cells with CNO in freely-
behaving mice substantially increased their voluntary locomotion
(by ≈150%; Fig. 3G; no such effect was found in control WT mice
injected with the same viral vector, in which the CNO-induced
change in locomotion was 49 ± 48.7%, n = 5, P = 0.3684 by one-
sample t test; t, df = 1.013, 4). Collectively, these data demonstrate
that the activity of GAD65LH cells is necessary for maintaining a
normal level of locomotion (Fig. 3 C and D), and sufficient for
stimulating locomotion (Fig. 3G).
Finally, we reasoned that if GAD65LH cells naturally promote
locomotion, then their activity should be associated with sponta-
neous/voluntary locomotion. To test this hypothesis, we measured
GAD65LH-GCaMP6s network activity using fiber photometry, and
quantified locomotion using a sensitive rotary treadmill, which could
resolve distances traveled as low as 1.8 mm (Fig. 4A and Materials
and Methods). We found that spontaneously initiated locomotion
bouts (defined as locomotion with a speed of >0.17 cm·s−1;Materials
and Methods) were associated with increased natural GAD65LH cell
activity (Fig. 4 B and C). Locomotion-associated GAD65LH cell
activity appeared to increase before movement was detected, and
persisted throughout the locomotion bouts (Fig. 4 A–C). To esti-
mate the temporal relationship between the natural GAD65LH cell
signals and locomotion initiation, we defined signal onset time using
a third derivative method (28), and also defined the steepest point
of GAD65LH signal rise as the peak in the first derivative (Fig. 4D).
The steepest rise of the perilocomotion GAD65LH signal occurred
approximately at movement onset, whereas the onset of GAD65LH
signal rise occurred ≈2 s before movement onset (Fig. 4E and
Discussion).
Collectively, these data provide correlative (Fig. 4) and causal (Fig.
3) evidence that GAD65LH cell activity drives locomotion in mice.
Discussion
Despite the long-recognized importance of the LH for main-
taining normal physical activity in mammals, including humans
(1–6, 29, 30), the functional relations of molecularly distinct LH
subnetworks remained poorly understood. Our study identifies
several properties of the GAD65LH subnetwork that reveal a
previously overlooked interplay between molecularly distinct LH
signals relevant for locomotion control. First, GAD65LH cells are
activated by orexin neurons, and are rapidly recruited by stress
in vivo in an orexin receptor-dependent manner. Second, natural
GAD65LH cell activity is necessary for maintaining normal levels
of locomotion, whereas experimentally induced GAD65LH cell
activity is sufficient to promote locomotion. Third, internally
initiated GAD65LH network bursts are associated with initiation
and maintenance of voluntary movement. When GAD65LH cells
were inactivated, reducing orexin receptor activity no longer
affected locomotion (Fig. 3D), consistent with the idea that
GAD65LH cells act as mediators of locomotion driven by natural
orexin signaling. These multiple lines of evidence demonstrate a
critical role for GAD65LH cells in driving normal locomotion,
and in acting as effectors of the orexin system.
In known brain controllers of voluntary action, such as the basal
ganglia, neural signals implicated in movement control appear
seconds before action initiation (e.g., figure 3 E and F of ref. 24).
These delays are comparable to the delays we observed between the
onset of the GAD65LH network bursts and movement initiation
(≈2 s; Fig. 4E). These long delays presumably imply multiple
downstream processing stages between GAD65LH cell signals and
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Fig. 2. Stress-induced, orexin-dependent control of GAD65LH cells in vivo. (A,
Left) Schematic of fiber photometry recording. (A, Center) GCaMP6s expression
in GAD65LH cells, and localization of recording site and optical fiber (repre-
sentative example of five brains). (A, Right) Example fluorescence trace during
free cage exploration for mice expressing GCaMP6s (blue) or EGFP (black) in
GAD65LH neurons (typical examples of n = 5 and n = 5 mice, respectively).
(B) Simultaneous measurement of membrane electrical activity and calcium
level in GAD65LH-GCaMP6s cells. (Top) Schematic of recording and examples of
two video frames from a cell injected with depolarizing current steps. (Bottom)
Example of simultaneous cell-attached and fluorescence recording from a
GAD65LH cell (typical example of n = 5 cells). (C) Examples of quantification of
data in B, showing the linear relationship between calcium level and spike
frequency in four different cells. (D) Group plot of slopes (taken from linear
regression fits) of relations between spike frequency and calcium level (n =
5 cells). (E, Left) GAD65LH-GCaMP6s signals aligned to immobilization stress (i.s.).
Heat maps of individual trials from one mouse, in the presence and absence of
orexin receptor antagonist SB-334867 (SB; 30 mg/kg i.p.; Materials and Meth-
ods), representative example of n = 4 mice. (E, Center) Averaged data for bouts
such as those bouts shown on the left. Each trace is the average response of
n = 4 mice (each n is a mean of four trials such as those trials shown on the left).
The GFP trace shows responses of GAD65-GFP mice (negative controls). (E,
Right) Mean calcium signals during i.s. (10–20 s) per mouse (each point repre-
sents one mouse, n = 4 mice). One-way repeated measures ANOVA: F(2,6) =
11.61; P = 0.0087, P values on the plot are from Tukey’s posttests.
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motor commands that drive muscle activity underlying locomotion.
When we attempted to determine downstream targets of GAD65LH
neurons by tracing their axon distribution in brains of GAD65LH-
ChR2-YFP mice, we found projections to multiple neural systems,
extending from the LH to the thalamus, ventral tegmental area,
cortical sensory areas, brainstem, and many hypothalamic nuclei
(Fig. S1). A comprehensive analysis of these downstream effectors
of GAD65LH cells will be included in future studies, because it is a
large task requiring the relative locomotor impacts of GAD65LH
cell targets to be deciphered. A specific question for such future
work would be whether the locomotion drivers described here, and
the classical basal ganglia pathways, operate in series or in parallel
to promote physical activity.
Related questions for future studies are what neurotransmitters
GAD65LH cells release at their many projection targets, and what
regulatory receptors they express. GAD65LH cells do not express
orexin or MCH neurotransmitters (21); note that this finding does
not contradict previous reports of GAD67 expression in MCH cells,
because GAD65 and GAD67 are not always coexpressed in the
hypothalamus (e.g., refs. 31, 32). We also found that the GAD65LH
cells are distinct from the previously studied LH neurons expressing
neuropeptide Y (NPY) or leptin receptor (33, 34) (Fig. S2 A and
B). It remains to be determined whether GAD65LH cells release
excitatory and/or inhibitory transmitters, because vesicular GABA
transporter (VGAT) is not always expressed in GAD65 neurons,
and some hypothalamic GAD65 neurons contain glutamatergic
markers (31, 32, 35). Indeed, we found that only 50% of the
GAD65LH cells contain VGAT, and that most (≈80%) VGATLH
cells are distinct from GAD65LH cells (Fig. S2 C and D). Thus, the
previous studies of VGATLH cells (36–39) likely targeted larger and
more heterogeneous cell populations than our study, which was
selective for GAD65LH cells. This fact may explain why the
VGATLH cell stimulation drove different behaviors [increased eating
and insignificant effect on locomotion (36, 39)] than the GAD65LH
cell stimulation (increased locomotion and no significant effect on
eating; Fig. 3 and Fig. S3). The latter findings presumably imply that
GAD65LH-stimulated locomotion is unlikely to be specifically mo-
tivated by hunger or directed toward a food goal. We note that in
some contexts, it may be evolutionarily advantageous to develop a
locomotion drive not directed toward a specific goal (e.g., food), but
toward a more general goal (e.g., change of place, physical escape). It
is thus tempting to speculate that the orexin-activated GAD65LH
cells may provide such a general locomotion drive that serves, for
example, to move the animal away from stresses that activate orexin
neurons (3, 10, 11, 13). Such an escape-like behavioral drive would
also be consistent with the observed GAD65LH cell dynamics during
capture, when the mouse is immobilized but the drive is high.
In summary, we found that physiological activity of GAD65LH
cells is vital for normal locomotion and identified orexin as a phys-
iological upstream regulator of GAD65LH activity. These findings
establish the GAD65LH cells as key players in intra-LH information
processing. Together with recent findings on roles of defined LH
neurons in eating and arousal (7, 36, 38), our results substantiate
specific LH circuits as orchestrators of key voluntary actions.
Materials and Methods
Gene Transfer. All procedures followed United Kingdom Home Office regu-
lations and were approved by the Animal Welfare and Ethical Review Panel
of the Francis Crick Institute. Adult male and female mice (at least 8 wk old)
were used for in vitro experiments. Male mice were used for behavioral
experiments, and kept on a standard 12-h/12-h light/dark cycle and on
standard mouse chow and water ad libitum. Mice were anesthetized with
isoflurane and injected with meloxicam (2 mg/kg of body weight, s.c.) for
analgesia. After placement into a stereotaxic frame (David Kopf Instruments),
a craniotomy was performed and a borosilicate glass pipette was used to
inject viral vectors bilaterally into the LH. Two injections (each 75 nL, delivered
at 75 nL·min−1) were made into the LH in each hemisphere (bregma: −1.30 mm,
midline: ±1 mm, from brain surface: 5.20 mm and 5.25 mm). Mice were
allowed to recover for at least 1 wk after surgery while single-housed.
sal           CNO          SB       SB+CNO
Cre-inducible hM3Dq
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Fig. 3. Effect of natural and evoked GAD65LH cell activity on locomotion.
(A, Left) Targeting scheme for hM4Di-mCherry. (A, Center) Localization
of hM4Di-mCherry. (A, Right) GAD65LH-hM4Di-mCherry cells at high
zoom (representative example of five brains). (B, Left) Effect of CNO on
GAD65LH-hM4Di cell firing. Spikes are truncated at 0 mV (representative
example of n = 5 cells). (B, Right) Group data, raw values, and means (red);
the on-plot P value is from a one-tailed, ratio-paired t test (t, df = 3.251, 4)
(n = 5 cells). APs, action potentials. (C) Effect of CNO on locomotion of
GAD65LH-hM4Di mice. Raw data and means are shown in red (Left), and
the same data are shown as % change (Right). On-plot P values are from a
one-tailed paired t test (t, df = 2.767, 4; Left) and from a two-tailed one-
sample t test (t, df = 3.001, 4; Right) (n = 5 mice). Corresponding negative
control data are described in Results. (D) Effects of SB-334867 (30 mg/kg
i.p.;Materials and Methods) on locomotion of GAD65LH-hM4Di mice in the
absence and presence of CNO. Repeated measures one-way ANOVA with
Geisser–Greenhouse correction [F(1.977,11.86) = 16.15; P = 0.0004, on-plot
values are P values from Tukey’s multiple comparison tests]. (E, Left) Targeting
scheme for hM3Dq-mCherry. (E, Center) Localization of hM3Dq-mCherry. (E,
Right) GAD65LH-hM3Dq-mCherry cells at high zoom (representative example
of five brains). (F, Left) Effect of CNO on GAD65LH-hM3Dq cell firing. Spikes
are truncated at 0 mV (representative example of n = 5 cells). (F, Right) Group
data, raw values, and means (red); on-plot P value is from a one-tailed ratio-
paired t test (t, df = 8.043, 4; n = 5 cells). (G) Effect of CNO on locomotion of
GAD65LH-hM3Dq mice. Raw data and means are shown in red (Left), and the
same data are shown as % change (Right). On-plot P values are from a one-
tailed paired t test (t, df = 2.638, 4; Left) and from a two-tailed one-sample
t test (t, df = 10.31, 4; Right) (n = 5 mice). Corresponding negative control data
are described in Results.
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Cre-dependent designer receptors exclusively activated by designer drugs
(DREADD) constructs (40, 41), rAAV8/hSvn-DIO-hm3D(Gq)-mCherry [2.2 × 1012
genome copies (gc)/mL; UNC Vector Core] or rAAV8/hSyn-DIO-hM4(Gi)-mCherry
(5.3 × 1012 gc/mL; UNC Vector Core), were used to measure the effect of cell
type-specific manipulation on locomotion. For ChR-assisted circuit mapping,
“FLEX switch” ChR2 constructs (42) were used. These constructs were either
AAV1.EF1.flox.hChR2(H134R)-mCherry.WPRE.hGH (8.78 × 1012 gc/mL) or AAV1.
EF1.DIO.hChR2(H134R)-YFP.WPRE.hGH (6.2 × 1012 gc/mL). For calcium imaging,
we used a GCaMP6s construct (23), rAAV9.CAG.Flex.GCaMP6s.WPRE.SV40 (2.74 ×
1013 gc/mL). Previously characterized and validated transgenic mouse lines (or
their crosses) were used where indicated: GAD65-Ires-Cre mice (43) bred in
homozygous (hom)-WT pairs with C57BL/6 mice, orexin-Cre mice (22) bred in
heterozygous (het)-WT pairs with C57BL/6 mice, GAD65-GFP mice (21) bred
in het-WT pairs with C57BL/6 mice, NPY-hrGFP mice (44) bred in het-WT pairs
with C57BL/6 mice, VGAT-Ires-Cre mice (45) bred in hom-WT breeding pairs
with C57BL/6 mice, and CAG-tdTomato mice (46) bred in hom-hom pairs.
Cell Type-Specific Deep-Brain Recordings in Awake BehavingMice.After injection
of Cre-dependent GCaMP6s into GAD65-Ires-Cre mice, the fiberoptic implants
were stereotaxically installed with the fiber tip above the LH (1.38 mm caudal
from bregma, 0.95 mm lateral from midline, and 5 mm ventral from brain
surface) and fixed to the skull as previously described (12, 13); this method is
expected to capture signals only from within 500 μm of the fiber tip (12). Fiber
tip locations were verified in each mouse by examining slices with a visible
fiber tract. For locomotion experiments and immobilization, mice also had a
custom-built, stainless-steel head-restraint implant glued to their skulls using
tissue-friendly cyanoacrylate (Histoacryl; TissueSeal). Fiber photometry was
performed as described by González et al. (13). Fluorescence signals were
converted to ΔF/F (%) values as follows: ΔF/F = 100 * (Fr − F)/F, where Fr is the
raw signal and F is the trial mean.
In Fig. 2E (immobilization stress experiments), mice were placed in a re-
cording cage and left for 10min; then, a trial consisting of 10 s of restraint stress
(holding the mouse head stationary inside the cage by clamping the head-fixed
restraint) was performed, based the method of González et al. (13). For each
mouse, four trials per day were performed (with intertrial intervals >5 min).
Trial blocks for drug condition (control, SB-334867, and recovery) were sepa-
rated by 48 h. The competitive orexin receptor antagonist SB-334867 (or 0.9%
NaCl and 10% DMSO as a control vehicle) was given i.p. 1 h before immobili-
zation stress. This antagonist has a higher affinity for orexin type-1 receptor
than for orexin type-2 receptor, but at higher concentrations, it antagonizes
orexin binding to both receptors (47). We used a single high dose of SB-334867
(30 mg/kg), based on previous studies with this compound (48, 49). To control
for circadian factors, all experiments were performed during the dark phase.
Quantifying Physical Activity. Locomotor activity was assessed after a single
i.p. dose of CNO or saline during the dark-phase in open home cages using
either video-tracking (Anymaze or Ethovision) or a rotary treadmill. Mice of
the same genotype were grouped according to vectors injected into their
brains, and all groups had a similar composition based on sex (male), age, and
body weight. For treadmill locomotion quantification, mice were head-
restrained in a sound-attenuated chamber where they could run on a disk
treadmill with a rotary encoder. The center of the animal’s head was such that
1° of rotation equated 1.8 mm of forward locomotion. The encoder gener-
ated a transistor-transistor logic (TTL) pulse every time the animal moved
1.8 mm. The pulses were collected by the same analogue-to-digital converter
as the photodetector signals for accurate time-stamping of GAD65-GCaMP6s
signals and locomotion. Locomotion bout onset was defined as the time of
crossing a velocity threshold of 0.17 cm·s−1, and locomotion bouts of at least
5 s in duration from this onset are illustrated in the analyses shown in Fig. 4C.
Brain Slice Optogenetics, Electrophysiology, and Imaging. Patch-clamp record-
ings combined with optogenetics were carried out as reported by Schöne et al.
(50). Briefly, LH slices were prepared at least 2 months after virus injection.
Coronal brain slices of 250-μm thickness containing the LH were cut while
immersed in ice-cold slicing solution. Slices were incubated for 1 h in artificial
cerebrospinal fluid (ACSF) at 35 °C, and then transferred to a submerged-type
recording chamber. Neurons containing fluorescent markers were visualized
with an Olympus BX61WI microscope with an oblique condenser and fluo-
rescence filters. Excitation light for ChR2 was delivered from a LAMBDA DG-
5 beam switcher (Sutter) with a xenon lamp and ET470/40-nm bandpass filter.
A 40× 0.8-N.A. objective was used to deliver 1-ms flashes of blue light
(∼10 mW/mm2) onto ChR2-containing axons around the recorded cell, and
postsynaptic responses were recorded at a range of potentials (0 to −90mV) in
each cell. For studying effects of orexin on membrane current (Fig. 1C),
voltage-clamp ramps from 0 to −120 mV were performed at 0.1 mV·ms−1, and
orexin-evoked current was then derived in each cell by subtracting the base-
line current from the orexin current at each potential and plotted at 10-mV
increments for visual clarity (Fig. 1C, Right). Functional ChR2 expression was
confirmed by recording light-activated action potentials in the target cells (n =
3 cells per group). For calcium imaging, brain slices were placed in a recording
chamber of a BX61WI Olympus microscope controlled by Olympus Fluoview
software (FV10-ASW version 4.0), perfused at 35 °C with ACSF. Confocal im-
aging was performed at 0.5 Hz with an Olympus 20× 0.50-N.A. objective, 488-
nm argon laser excitation, and 500- to 545-nm emission collection. Motion and
bleach corrections were applied if needed (StackReg plug-in, ImageJ; NIH). A
region of interest (ROI) containing each GCaMP6s-positive neuron was se-
lected via ROI manager in ImageJ. The mean fluorescence of each ROI was
extracted for each frame. These raw fluorescence (Fr) values were normalized
to produceΔF/F values, where F is the mean baseline before orexin application
and ΔF = (Fr − F). Simultaneous brain slice cell-attached recordings and calcium
imaging (Fig. 2 B and C) were performed as reported by González et al. (13).
Because the cell-attached experiments, which were necessary to preserve
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Fig. 4. Natural GAD65LH cell dynamics underlying voluntary movement.
(A) Scheme of experimental setup, with example raw data illustrating temporal
alignment of locomotion initiation (upward deflections on the orange trace) and
GAD65LH signal (typical example of n = 4 mice). (B) Example of rotary encoder
pulses converted to locomotion velocity (orange), illustrating coquantification
of natural GAD65LH cell dynamics (blue) and locomotion (typical example of
n = 4 mice). (C) Peri-event plots aligned to onset of locomotion bouts [dashed
black line indicates the threshold locomotion criterion (0.17 cm·s−1) for bout
onset]. (Top) Heat maps of individual trials from one mouse. (Bottom) Group
data for bout averages in GAD65LH-GCaMP6s and GAD65LH-GFP (mean ± SEM).
Statistics for data binned in 2-s bins: one-way repeated measures ANOVAs for
control GFP group [n = 3 mice; F(9,18) = 0.8308, P = 0.5974] and for GCaMP6s
group [n = 4 mice; F(9,27) = 4.630, P = 0.0009]. (D) Illustration of the third and
first derivative methods used to measure the timing of GAD65LH-GCaMP6s signal
onset (ON) and steepest rise (S) relative to locomotion onset (dashed black line,
defined as in B) (typical example of n = 4 mice). (E) Quantification of latencies of
GAD65LH-GCaMP6s signal onsets and steepest rises to locomotion initiation.
Signal onset occurred at −2.22 ± 0.29 s (P < 0.0001 by two-tailed one-sample
t test; t, df = 7.572, 11). The steepest rise occurred at −0.35 ± 0.22 s (P = 0.3139 by
two-tailed one-sample t test; t, df = 1.055, 11).
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cytosolic integrity and thus in vivo-like GCaMP signals, do not measure trans-
membrane potential, it is possible that the GCaMP signal is increased by
interspike depolarization as well as by the depolarization during the spikes.
Chemicals and Solutions. For brain slice recordings, ACSF and ice-cold slicing
solution were gassed with 95% O2 and 5% CO2, and contained the following:
125 mM NaCl ACSF, 2.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 1.2 mM NaH2PO4,
21 mM NaHCO3, 2 mM D-(+)-glucose, 0.1 mM Na
+-pyruvate, and 0.4 mM
ascorbic acid. The slicing solution contained 2.5 mM KCl, 1.3 mM NaH2PO·H20,
26.0 mM NaHCO3, 213.3 mM sucrose, 10.0 mM D-(+)-glucose, 2.0 mM MgCl2,
and 2.0 mM CaCl2. For standard whole-cell recordings, pipettes were filled
with intracellular solution containing the following: 120 mM K-gluconate,
10 mM KCl, 10 mM Hepes, 0.1 mM EGTA, 4 mM K2ATP, 2 mM Na2ATP,
0.3 mM Na2GTP, and 2 mM MgCl2 (pH 7.3) with KOH. Concentrations used
were as follows: 300 nM orexin-A; 5 μM CNO; synaptic blocker mix: 50 μM
D-AP5, 10 μM picrotoxin, 10 μM CNQX, and 10 μM CGP 35348; and 3 μM
gabazine. For in vivo chemogenetic manipulations, CNO was injected i.p. at
5 mg/kg (experiments involving hM4Di) or at 0.5 mg/kg (experiments involving
hM3Dq). All chemicals were from Sigma or Tocris Bioscience.
Histochemistry. For the immunolabeling of pSTAT3 in Fig. S2, 30-μm cry-
osections of leptin-injected GAD65-GFP mice were pretreated with H2O2,
NaOH, glycine, and SDS. Staining for pSTAT3 was done with rabbit anti-
pSTAT3 lgG (no. 9131, 1:500; Cell Signaling Technology) sera overnight as
the primary antibody and Alexa 555-conjugated donkey to rabbit IgG
(A-31572, 1:500; Life Technologies) as the secondary antibody (51). In che-
mogenetic experiments, actuator targeting to LH (Fig. S4) was verified in
fixed sections prepared as reported by González et al. (12).
Statistical Analysis. Statistical tests and descriptive statistics were performed as
specified in the figure legends. In each experimental dataset at the cellular
level, each n was a different cell (no repeated trials from the same cell were
used as n values) and cells from at least three mice were analyzed. Before
performing parametric tests, data were assessed for normality with a D’Ag-
ostino–Pearson omnibus test or Kolmogorov–Smirnov test for small sample
sizes, and variances were assessed for homogeneity with a Brown–Forsyth test.
To compare interactions within normally distributed data with repeated
measurements, repeated measures ANOVA was used, with multiple compari-
son tests where appropriate. Analysis was performed with GraphPad Prism,
MATLAB (The MathWorks, Inc.), and ImageJ.
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